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Summary
Hyponatraemia is a common electrolyte disturbance 
with multiple causes. We present a case of a 49-year-
old Caucasian female with cholangiocarcinoma, who 
had a hyponatraemia which was initially assumed to 
be based on a syndrome of inappropriate antidiuretic 
hormone secretion as paraneoplastic phenomenon. 
at physical examination, hyperpigmentation was seen 
and multiple episodes with syncope were reported. 
subsequent endocrine assessment with a synthetic 
adrenocorticotropin hormone (aCtH) stimulation test 
and measurement of aCtH levels revealed primary 
adrenal insufficiency also known as Morbus addison. 
We started hydrocortisone and fludrocortisone 
replacement therapy, resulting in resolving of symptoms, 
hyponatraemia and hyperpigmentation. BaCkground 
Hyponatraemia is a common clinical problem with 
a multifactorial aetiology. The general incidence 
of hyponatraemia (serum sodium <136 mEq/L) in 
hospitalised patients is 30% and in 2.6% serum 
sodium is <124 mEq/L.1 One of the causes of hypo-
natraemia is hypocortisolism. Early recognition of 
this disease is of vital importance, because hypoco-
rtisolism is a potentially life threatening condition 
and presenting symptoms are often non-specific.
The first diagnostic steps in hyponatraemia are 
to confirm a hypo-osmolar hyponatraemia using 
serum osmolality, this measurement should match 
the calculated osmolality. Urinary osmolality is 
also necessary and measures ADH activity, which 
is present when urinary osmolality ≥100 mOs/kg. 
Urinary sodium can help determine if sodium loss 
is renal of non-renal. The use of diuretics should 
always be considered, as it makes urinary sodium 
and osmolality more difficult to interpret.
After confirming a hypotonic (serum osmo-
lality <275 mOsm/kg) hyponatraemia, in absence 
of ADH activity, the differential diagnosis includes 
primary polydipsia, tea and toast and beer drinkers 
hyponatraemia. If urinary osmolality ≥100 mOs/
kg, urinary sodium and assessment of a patients’ 
volume status are needed.2
A hyponatraemia with a low urinary sodium 
(<30 mmol/L) and a hypovolaemic state can be 
the result of vomiting, diarrhoea, sequestration of 
fluid and recently stopped diuretics. If the patient 
is hypervolaemic, cardiac failure, liver cirrhosis and 
nephrotic syndrome needs to be considered.
Hyponatraemia with a high urinary sodium 
(≥30 mmol/L) and a hypovolaemic state can also be 
the result of vomiting, but also the use of diuretics 
or primary adrenal insufficiency. If the patient is 
Figure 1 Skin hyperpigmentation of a Caucasian 
female.
Figure 2 Normal skin colour after hydrocortisone 
treatment.
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euvolaemic secondary adrenal insufficiency and SIADH need to 
be considered.
In case of hyponatraemia without hypotonicity, other condi-
tions should be considered. This can be the result of a hypergly-
caemia or exogenous solute (ie, mannitol, intravenous immune 
globulines). In these situations, water is drawn from intracellular 
to the extracellular space, resulting in a lowered serum sodium 
concentration, but hypertonicity. Another consideration is a 
pseudohyponatraemia, which is a laboratory miscalculation of 
the serum sodium. This phenomena can be hyperlipidaemia, 
hyperproteinaemia or obstructive jaundice. The electrolyte 
concentration is measured in plasma, which normally consists of 
about 93 percent water and seven percent solids, mostly proteins 
and fats. The serum sodium concentration is determined based 
on the measured plasma sodium concentration and the estimated 
percentage of water. An increase in solids leads to a lower water 
percentage, and therefore a miscalculation of the serum sodium, 
however tonicity remains normal.2
In this article, we present a case of hyponatraemia and hyper-
pigmentation caused by a Morbus Addison in a patient with 
jaundice caused by a pancreatic carcinoma. Initially, it was inter-
preted as SIADH, but hyperpigmentation was the vital clue in 
diagnosing primary hypocortisolism.
CaSe preSenTaTion
A 49-year-old Caucasian woman with a medical history of 
auto-immune hyperthyroidism was hospitalised for analysis of 
painless jaundice under suspicion of a cholangiocarcinoma. At 
presentation, she had a hypotonic hyponatraemia (serum sodium 
124 mmol/L, measured serum osmolality 255 mOsm/kg, calcu-
lated serum osmolality 260.3 mOsm/kg) combined with a urine 
osmolality of 678 mOsm/kg and a urine sodium of 219 mmol/L. 
Awaiting further diagnostics (eg, morning serum cortisol, 
thyroid-stimulating hormone and thyroxine) she was initially 
treated for the assumed diagnosis of a syndrome of inappropriate 
antidiuretic hormone secretion (SIADH) as paraneoplastic effect 
of a suspected cholangiocarcinoma. However, fluid restriction 
failed to raise the serum sodium level. In addition, on further 
inquiry our patient reported multiple episodes of syncope in the 
previous weeks. Closer physical examination showed a severe 
hyperpigmentation, which our patient reported to be worsened 
over the last year (figure 1). Furthermore, our patient is 177 cm 
tall and has a body weight of 55.15 kg with a BMI of 17.6 kg/m2. 
The combination of severe hyperpigmentation, hyponatraemia 
and episodes of syncope and orthostatic hypotension (with 
blood pressure values between 73/50 mmHg and 90/52 mmHg 
and a heart rate of 75/minute) made hypocortisolism caused by 
primary adrenal insufficiency, also known as Morbus Addison, 
the most likely diagnosis.
inveSTigaTionS
To confirm our hypothesis of primary adrenal insufficiency, we 
performed a synthetic adrenocorticotropin hormone (ACTH) 
stimulation test (synacthen 250 µg) showing a cortisol decrease 
from 217 nmol/L to 207 nmol/L at 30 minutes. Basal plasma 
ACTH level was 492 pmol/L (normal range 0–11 pmol/L) and 
adrenal auto-antibodies were positive. Serum renin concentra-
tion was 1520 µU/mL (normal range 5–60 µU/mL) whereas 
serum aldosteron was not detectable (<50 pmol/L). These 
results confirmed the diagnosis of Morbus Addison. Abdominal 
CT-scan, performed in the diagnostic process of the suspected 
cholangiocarcinoma, showed no abnormalities of the adrenal 
glands.
diFFerenTial diagnoSiS
Our patient had a hypotonic hyponatraemia (serum sodium 
124 mmol/L, serum osmolality 255 mOsm/kg, calculated serum 
osmolality 260.3 mOsm/kg) combined with a urinary osmo-
lality of 678 mOsm/kg and a urinary sodium of 219 mmol/L. 
Pseudohyponatraemia, for example as a result of jaundice, was 
excluded as cause because the hyponatraemia was hypotonic 
hyponatraemia.
She was initially assessed as euvolaemic, leading to a differ-
ential diagnosis of SIADH. In daily practice, SIADH is often 
assumed to be the cause of hyponatraemia, even before the 
diagnostic work-up is completed. This was also the case in our 
patient, in whom treatment for SIADH was initiated before the 
adrenal insufficiency was adequately ruled out. Recent guidelines 
also state that a SIADH diagnosis requires exclusion of other 
possible causes of hyponatraemia, like adrenal insufficiency.3 In 
our case, the assumed diagnosis SIADH resulted in delay in the 
final diagnosis.
TreaTmenT
Our patient had both an auto-immune hyperthyroidism and a 
Morbus Addison and was diagnosed with a polyglandular auto-
immune syndrome type 2.4 We started cortisol replacement treat-
ment with hydrocortisone 50 mg intravenous once, followed 
by oral hydrocortisone 20 mg–10mg–10mg per day. The dose 
was doubled because of simultaneous use of rifampicine. We 
also started fludrocortisone 62.5 µg per day. This treatment was 
indicated because in our patient, there was a primary cause of 
adrenal insufficiency. Therefore, mineral corticosteroid is also 
lacking and substitution is essential.
ouTCome and Follow-up
Our patient was treated for her adrenal insufficiency resulting in 
full recovery of symptoms and a normalisation of hyponatraemia 
in 4 days. Also, within 2 weeks the hyperpigmentation resolved 
(figure 2).
Analysis for the jaundice of our patient initially led to the 
suspicion of cholangiocarcinoma, but histological examina-
tion revealed pancreatic adenocarcinoma. She underwent a 
pancreaticoduodenectomy. The operation was, unfortunately, 
complicated by intra-abdominal bile acid leakage treated with 
a temporary percutaneous biliairy stent. Unfortunately, during 
oncological follow-up metastasis and later also local recurrence 
of the pancreatic carcinoma were diagnosed, therefore palliative 
chemotherapy was given, despite this effort our patient deceased 
2 years after diagnosis.
diSCuSSion
In this article, we present a case of hyponatraemia and hyper-
pigmentation caused by Morbus Addison in a patient with jaun-
dice as a result of pancreatic carcinoma. Morbus Addison is a 
rare disease, and pancreatic carcinoma occurring simultaneously 
is, to our knowledge, never reported before. It did result in an 
inappropriate initial diagnosis, as SIADH is a common finding in 
patients with malignancies. We did find a case of a woman with 
autoimmune polyglandular syndrome type 2 having the combi-
nation of hyponatraemia, hyperpigmentation caused by Morbus 
Addison with a previous autoimmune Hashimoto’s thyroiditis.5 
In our case, undersubstitution of levothyroxine could have 
contributed to the hyponatraemia, however, thyroid hormone 
concentration was normal with a levothyroxine dose of 100 µg/
day.
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Hyponatraemia in patients with hypocortisolism is due to 
aldosterone deficiency, leading to renal sodium loss, and is 
enhanced by water retention via an increased release of antid-
iuretic hormone (ADH) in response to a reduction in systemic 
blood pressure and cardiac output caused by cortisol deficiency. 
The ADH response is maintained by cortisol deficiency because 
the direct negative feedback of cortisol on ADH release is 
declined.6 This explains why in hypocortisolism hyponatraemia 
does not improve with only fluid restriction.
Hyperpigmentation in primary adrenal insufficiency is caused 
by an increased production of α-melanocyte-stimulating-hor-
mone (αMSH).7 Both αMSH and ACTH originate from the 
pro-hormone peptide pro-opiomelanocortin (POMC). In 
primary adrenal insufficiency POMC production is strongly 
increased in response to the fall in cortisol levels with concomi-
tant release of αMSH causing a bronze hyperpigmentation.
Early recognition of Morbus Addison is of vital importance, 
because hypocortisolism can be a life threatening condition in 
case of physical stress as activation of the hypothalamic-pitu-
itary-adrenal axis is an essential response during illness. Further-
more, Morbus Addison often presents with non-specific 
symptoms, which makes hyperpigmentation an important clue in 
the diagnosis.4
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learning points
 ► Hyponatraemia can be the first presentation of Morbus 
Addison.
 ► In patients with hyponatraemia and co-morbidity 
predisposing to SIADH, adrenal insufficiency should always be 
considered as contributory factor or primary cause.
 ► Hyperpigmentation caused by increased production of 
α-melanocyte-stimulating-hormone can be a vital clue to 
consider primary hypocortisolism, also when other serious 
co-morbidity is present.
 ► Hyperpigmentation in this case of Morbus Addison resolved 
within 2 weeks after starting cortisol replacement therapy.
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